Are you Dr. Corn?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 82 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161- Is this information wrong?
Summary
- Dr. Paul Corn, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Oklahoma. He is affiliated with University of Texas M.D. Anderson Cancer Center and is an Associate Professor at Division of Cancer Medicine.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1996 - 1999
University of ChicagoResidency, Internal Medicine, 1993 - 1996
Georgetown University School of MedicineClass of 1993
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 2005 - 2024
OK State Medical License 2020 - 2021
PA State Medical License 2000 - 2004
MD State Medical License 1996 - 2000
Clinical Trials
- Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer Start of enrollment: 2008 Feb 01
- TKI258 in Castrate Resistant Prostate Cancer Start of enrollment: 2010 Apr 07
- Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2012 Mar 30
- Join now to see all
Publications & Presentations
PubMed
- Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma.Rhenita Amirtharaj, Lianchun Xiao, Dzifa Y Duose, Shufang Wang, Surena F Matin, Mehrad Adibi, Amishi Y Shah, Omar Alhalabi, Paul Corn, Charles Guo, Suzanne Lange, Suma...> ;The Journal of Urology. 2024 Apr 10
- Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer.Koontz, B., Halabi, S., Howard, L., Anand, M., George, D., Lee, W., Fecteau, R., Hoffman, K., Zhang, T., Berry, W., Harrison, M., Corn, P., Armstrong, A.> ;Prostate Cancer and Prostatic Diseases. 2024 Feb 22
- Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments.Slack-Tidwell, R., Zhu, K., San Lucas, F., Siddiqui, B., Soundararajan, R., Viscuse, P., Zhang, M., Rohra, P., Konnick, E., Pilie, P., Logothetis, C., Corn, P., Subudh...> ;Cancers. 2023 Dec 14
- Join now to see all
Press Mentions
Cancer Death Rates down but Racial Disparities Persist Among Black Men and WomenJanuary 12th, 2023
Expert Sees Checkpoint and PARP Inhibitors Building on mCRPC SuccessMarch 14th, 2017
Study Identifies Possible New Combination Chemotherapy for Patients with Advanced Prostate CancerMay 30th, 2015
Grant Support
- Regulation Of The Von Hippel-Lindau ProteinNational Cancer Institute2004–2007
- Regulation Of The Von Hippel-Lindau ProteinNational Cancer Institute2003
Hospital Affiliations
University of Texas M.D. Anderson Cancer CenterHouston, Texas
